Posterior Reversible Encephalopathy Syndrome (PRES) in Children Undergoing Allogeneic Stem Cell Transplantation

1. Goni Lee, Seung Eun Lee, Kyung-Ha Ryu, and Eun Sun Yoo. Posterior reversible encephalopathy syndrome in pediatric patients undergoing treatment for hemophagocytic lymphohistiocytosis: clinical outcomes and putative risk factors. Blood Res. 2013 Dec; 48(4): 258–265. doi: 10.5045/br.2013.48.4.258.10.5045/br.2013.48.4.258389438424466550Open DOISearch in Google Scholar

2. Riccardo Masetti, Duccio Maria Cordelli, Daniele Zama, Francesca Vendemini, Carlotta Biagi, Emilio Franzoni, Andrea Pession. PRES in Children Undergoing Hematopoietic Stem Cell or Solid Organ Transplantation. Pediatrics:135(5); 890-902 doi:10.1542/peds.2014-232510.1542/peds.2014-232525917987Open DOISearch in Google Scholar

3. D Zama, R Masetti, DM Cordelli, et all. Risk factor analysis of posterior reversible encephalopathy syndrome after allogeneic hematopoietic SCT in children. Bone Marrow Transplantation (2014) 49, 1538–154010.1038/bmt.2014.18225133894Search in Google Scholar

4. Javid Gaziev, Simone Marziali, Katia Paciaroni et all. Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies. Biology of Blood and Marrow Transplantation Journal, 2017. 23:9;1531-1540. doi: 10.1016/j. bbmt.2017.05.033.10.1016/j.bbmt.2017.05.03328602890Open DOISearch in Google Scholar

5. K Straathof, P Anoop, Z Allwood, J Silva, O Nikolajeva, R Chiesa, P Veys, PJ Amrolia and K RaoLong-term outcome following cyclosporine- related neurotoxicity in paediatric allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation (2017) 52, 159–162 doi: 10.1038/bmt.2016.232.10.1038/bmt.2016.23227643866522013327643866Open DOISearch in Google Scholar

6. Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol 2013; 88: 301–305. doi: 10.1002/ajh.23402.10.1002/ajh.234022346037823460378Open DOISearch in Google Scholar

7. Johnston L, Florek M, Armstrong R, et al. Sirolimus and Mycophenolate Mofetil as Graft-versus- Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation. Bone marrow transplantation. 2012;47(4):581-588. doi:10.1038/bmt.2011.104.10.1038/bmt.2011.104316305521552302Open DOISearch in Google Scholar

8. Noè A, Cappelli B, Biffi A, Chiesa R, Frugnoli I, Biral E et al. High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome. Ital J Pediatr 2010; 36:14. doi: 10.1186/1824-7288-36-14.10.1186/1824-7288-36-14282957220181110Search in Google Scholar

9. Erer B, Polchi P, Lucarelli G, Angelucci E, Baronciani D, Galimberti M et al. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors. Bone Marrow Transplant 1996; 18: 157–162.Search in Google Scholar

10. Stübgen J-P. Posterior reversible encephalopathy syndrome (PRES) after granulocyte-colony stimulating factor (G-CSF) therapy: a report of 2 cases. J Neurol Sci 2012; 321: 35–38. doi: 10.1016/j.jns.2012.07.Search in Google Scholar